$CC

Martinko Joseph T. purchased $30K of CC

Martinko Joseph T. (See Remarks) purchased 1,940 shares of Chemours Co (CC) at $15.47 on 2026-08-07.

Original reporting
SEC EDGAR · Martinko Joseph T.
Published Aug 11, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market purchase amount, price, and post-transaction holdings; it does not include any operational or financial update.

02

Market read

Traders may note the insider buy as a minor sentiment input, but there is no fundamental catalyst in the text.

03

What to watch

The article does not state the insider’s broader trading history, intent, or whether the purchase was part of a larger pattern, limiting signal quality.

Relevance 4/10Novelty 3/10Timing: Form 4 filed 2026-08-11, transaction dated 2026-08-07.

Background

The article is a SEC Form 4 insider transaction disclosure for Chemours (CC) by officer Martinko Joseph T.

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours (CC) disclosed an officer open-market purchase of 1,940 shares at $15.4700 on 2026-08-07 via Form 4 filed 2026-08-11.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine Form 4 insider transaction with modest size ($30,008.73) and no accompanying guidance, contract, or operational change.

Market effects

No clear sector read-through; this is company-specific insider activity without new sector data.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions and may not reflect a strong forward view, especially without a 10b5-1 plan.

Key entities

  • Chemours Co

    Subject of the Form 4 insider transaction disclosure.

  • Martinko Joseph T.

    Officer who purchased 1,940 shares of CC at $15.4700 on 2026-08-07.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCMedAI 8/10

Environmental groups allege Chemours hasn't met PFAS limits agreement

Cape Fear River Watch alleges Chemours has failed to meet pollution limits agreed upon in a 2019 consent order, claiming the company's groundwater and air emissions controls are inadequate. Chemours disputes these claims, stating it has spent $1.2 billion complying with the order. The environmental group filed a formal notice, citing high levels of PFAS in surface water and groundwater around the plant.

$CCMed

Chemours (CC) Shares Jumped, What Is Behind The Latest Move?

Chemours (CC) shares rose 3.10% after agreeing to a settlement with North Carolina and nearby communities over emissions. The stock is at $14.98, down 29.24% over 90 days. Analysts view it as undervalued at a fair value of $19.78, citing growth in advanced materials and cost optimization. However, PFAS liabilities and regulations pose risks.

$CCMedAI 8/10

What Chemours (CC)'s PFAS Settlement Means For Shareholders

Chemours (CC), DuPont, and Corteva agreed to a US$455 million settlement over PFAS emissions, shared equally. Payments will span 15 years, adjusting cost accounting under a US$4 billion cap. Chemours aims to recover profits by 2029, with revenue and earnings projections of US$6.6 billion and US$686.0 million, respectively, despite current losses. Analysts highlight operational execution and PFAS liability management as key factors.

$CCMedAI 8/10

North Carolina, Chemical Companies Reach $455M PFAS Contamination Settlement

Chemours, DuPont, and Corteva agreed to pay $455M over 15 years to settle PFAS contamination claims in North Carolina. Chemours will cover half, with the rest split between DuPont and Corteva. The funds will support state and local remediation efforts. The companies have already spent or committed significant sums for cleanup and penalties.